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Abstract
Background: Sleep disordered breathing (SDB) such as sleep apnea is associated with cardiovascular disease in the
general population. However, little is known about the cardiovascular risks of SDB in patients with end-stage renal
disease (ESRD).
Methods: We identified Medicare fee-for-service beneficiaries aged ≥67 years initiating dialysis between 2004 and
2009. Outcomes of interest included all-cause mortality, incident myocardial infarction, ischemic stroke, and atrial
fibrillation. We compared patients with and without diagnosed SDB using Cox proportional hazards regression.
Results: Between 2004 and 2009, 184,217 older patients developed ESRD, of whom 15,121 (8.2 %) were previously
diagnosed with SDB. Patients diagnosed with SDB were younger, more likely to be male and Caucasian, less Medicaid
eligible, had more non-Nephrology clinic visits, higher body mass index, and more comorbidity. In analyses adjusting
for demographics and BMI, diagnosed SDB was associated with higher risk of death and atrial fibrillation, but not
associated with myocardial infarction or ischemic stroke risk. After further adjustment for all baseline characteristics,
diagnosed SDB was associated with slightly lower risks of death (hazard ratio [HR]: 0.93, 95 % confidence interval [CI]:
0.91–0.96), myocardial infarction (HR: 0.92, CI: 0.87–0.98), and ischemic stroke (HR: 0.90, 95 % CI: 0.82–0.98), and not
associated with atrial fibrillation (HR: 1.02, CI: 0.98–1.07).
Conclusions: In older patients initiating dialysis in the U.S., diagnosed SDB was weakly associated with lower risks of
death and important cardiovascular outcomes, thus adding to the list of established risk factors that are paradoxically
associated with cardiovascular outcomes in the ESRD population.
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Background
Cardiovascular disease is the leading cause of death
among patients with end-stage renal disease (ESRD), ac-
counting for 38 % of deaths in the incident U.S. dialysis
population between 2008 and 2010 [1]. Sleep-disordered
breathing (SDB) encompasses a group of disorders char-
acterized by abnormalities of respiratory pattern causing
arousals and affecting the quantity of ventilation or ar-
terial oxygen saturation during sleep [2], the most com-
mon being obstructive sleep apnea. It is increasingly
recognized as a contributor to cardiovascular disease
and has been shown to be independently associated with
mortality [3–5] and cardiovascular events including
stroke [3, 6–8], coronary artery disease [9–11], and car-
diac arrhythmias including atrial fibrillation [12–16] in
the general population. Treatment of SDB with continu-
ous positive airway pressure (CPAP) has been shown to
reduce systemic blood pressure in randomized studies
[17] and reduce risk of cardiovascular events and death
in observational studies [18–21], though evidence is con-
flicting [22].
It has been suggested that SDB is highly prevalent in
patients with ESRD (>50 %) due to shared risk factors
such as the metabolic syndrome [23, 24], and potentially
some ESRD-specific factors including fluid shifts and
overload, airway edema, uremia, and altered central and
peripheral chemosensitivity [25–27].
Little is known about SDB and cardiovascular risk in
patients with ESRD. We characterized the prevalence
and features of diagnosed SDB in a large population of
older patients initiating dialysis and hypothesized that
diagnosed SDB was associated with all-cause mortality
and the cardiovascular events of myocardial infarction
(MI), ischemic stroke, and atrial fibrillation.
Methods
Study population
We used data from the United States Renal Data Sys-
tem (USRDS), and identified all patients over the age
of 67 years who initiated maintenance dialysis be-
tween 2004 and 2009 and required that they had at
least two years of continuous Medicare Parts A&B
coverage at dialysis initiation. Patients with a history
of MI, ischemic stroke, or atrial fibrillation in the two
years preceding ESRD were excluded from the re-
spective analyses of that outcome.
Sleep disordered breathing
Patients diagnosed with SDB prior to initiation of main-
tenance dialysis were identified using International Clas-
sification of Diseases (9th Revision; ICD-9) diagnosis
codes from Medicare billing claims during the two years
preceding ESRD. We required a single inpatient code or
two separate outpatient codes on different days to
establish the diagnosis [28]. Prior to October 2005,
780.57 (sleep apnea not otherwise specified, NOS) was
the sole ICD-9 code for SDB. In October 2005, several
new ICD-9 codes for SDB were introduced. We defined
SDB using codes 780.57, 327.2x (organic sleep apnea),
780.51 (insomnia with sleep apnea NOS) and 780.53
(hypersomnia with sleep apnea NOS) to capture patients
diagnosed with SDB in both time periods. Because we
found that very few (<5 %) patients received a diagnosis
of SDB between 1996 and 2003 (Table 1), we limited our
cohort to those initiating dialysis in the years 2004
through 2009. Given the changes in ICD-9 coding, we
conducted a sensitivity analysis restricted to incident
ESRD patients from 2007 through 2009 using only the
more specific ICD-9 code 327.23 (obstructive sleep
apnea; adult).
Outcomes
The outcomes of interest were all-cause mortality and
incident MI, ischemic stroke, and atrial fibrillation.
Death was ascertained using the USRDS patient file. We
defined MI by the presence of one inpatient claim with
an ICD-9 primary diagnosis code of 410.xx or a second-
ary diagnosis code of 410.x1 or death from MI. Ischemic
stroke was defined as one inpatient claim with a primary
diagnosis code of 436, 437.1, 433.x1, or 434.x1 or death
from stroke. Atrial fibrillation was defined as one in-
patient or two outpatient billing claims with a diagnosis
code of 427.3x.
For the outcome of death, follow-up was censored at
end of study, December 31, 2009. For the outcomes of
MI, stroke, and atrial fibrillation, follow-up was censored
at end of study, loss of Medicare fee-for-service cover-
age, or death. We did not censor at kidney transplant-
ation, which was a rare occurrence (~1.1 % of patients)
and similar between exposure groups.
Table 1 Diagnosis of sleep disordered breathing and
obstructive sleep apnea by year, 2004–2009
Year Incident ESRD (N) SDB (N) SDB % OSA (N) OSA %
2004 31,741 1822 5.43 – –
2005 31,553 2193 6.50 64 0.19
2006 29,715 2374 7.40 667 2.08
2007 27,401 2651 8.82 1243 4.14
2008 26,501 2864 9.75 1782 6.07
2009 25,753 3307 11.40 2462 8.47
Sleep disordered breathing (SDB) was defined as one inpatient or two
separate outpatient Medicare billing claims with ICD-9 codes of “organic sleep
apnea” (327.2x), “hypersomnia with sleep apnea NOS” (780.53), “insomnia with
sleep apnea NOS” (780.51), or “sleep apnea NOS” (780.57)
Obstructive sleep apnea (OSA) was defined as one inpatient or two separate
outpatient Medicare billing claims with ICD-9 codes of “obstructive sleep
apnea (adult)” (327.23) only
Until October 2005, “sleep apnea NOS” (780.57) was the sole ICD-9 code for
sleep disordered breathing, after which several new codes were added encom-
passing sleep apnea and related disorders
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Patient characteristics
From the USRDS patient file, we gathered demographic
information including age, sex, race (white; black; other),
Hispanic ethnicity, and cause of ESRD. Presence of a
large number of pre-existing comorbidities was ascer-
tained using specific ICD-9 codes from the two years
preceding ESRD by at least one inpatient or two out-
patient claims on different days. We ascertained dual
Medicaid-Medicare eligibility, serum albumin, and body
mass index (BMI) at initiation of maintenance dialysis
from the Medical Evidence Report (form CMS-2728).
Estimated glomerular filtration rate was provided in the
USRDS based on reported serum creatinine concentra-
tions. We also quantified health care utilization in the
year prior to initiation of dialysis by determining
whether the patient was in a skilled nursing facility, the
number of days spent in hospital, and the number of
non-nephrology outpatient visits.
Statistical analysis
Our cohort was divided into patients with versus with-
out diagnosed SDB. Baseline categorical variables were
expressed as percentages and continuous variables as
medians and interquartile range. Unadjusted incidence
rates, defined as the number of events over person-time
observed, were calculated for each outcome.
Time from incident ESRD to each outcome of interest
was analyzed using the Kaplan-Meier method and Cox
proportional hazards regression. We estimated hazard
ratios (HR) and their corresponding 95 % confidence in-
tervals (CI) using four nested Cox models for each out-
come: 1) unadjusted; 2) adjusted for age, sex, race,
Hispanic ethnicity, and dual Medicaid-Medicare eligibil-
ity; 3) additionally adjusted for BMI (including BMI
squared); 4) additionally adjusted for all covariates listed
in Table 2. Since we removed patients with a history of
the outcomes of interest, the corresponding covariate
was not included in the final model. All models were
stratified by incident year. We used log (−log) survival
curves and plots of Loess-smoothed scaled Schoenfeld
residuals to assess the adequacy of the Cox proportional
hazards models.
About 29 % of patients had at least one variable miss-
ing, with the proportion of variables with data missing
ranging from less than 0.5 % (dialysis modality) to 25 %
(albumin; Table 2). We assumed the data to be missing
at random and used multiple imputation (using SAS
PROC MI) through the joint modeling approach to ob-
tain 7 imputed datasets [29]. One dataset was used for
model checking and to the remaining 6 we fitted the
stratified Cox proportional hazard models. The results
of the 6 fitted models were then combined using the
rules described by Little and Rubin (using SAS PROC
MIANALYZE) [30]. Imputation was done separately for
each outcome analyzed and the imputation model in-
cluded all variables used in the analyses. Height or
weight was used to impute BMI if only one was avail-
able. Complete case analyses, a less preferred option,
were also conducted and yielded quantitatively similar
results albeit with wider confidence limits owing to the
reduced sample size (results not shown).
This study was approved by an institutional review
board at Stanford University. All analyses were con-
ducted using SAS software, version 9.3 (www.sas.com)
and R (www.r-project.org).
Results
We identified 184,217 patients who developed ESRD be-
tween 2004 and 2009 and met inclusion criteria for our
primary cohort. Of these, 15,121 (8.2 %) were diagnosed
with SDB. Diagnosis of SDB increased steadily through-
out the study period, from 5.4 % in 2004 to 11.4 % in
2009 (Table 1). Patients with diagnosed SDB (SDB+)
were slightly younger, more often male and Caucasian,
and had higher prevalence of a wide range of pre-
existing comorbidities as compared to patients without
diagnosed SDB (SDB-; Table 2).
Mortality
During a mean follow up of 1.60 years (range 0–6 years),
8248 (54.6 %) SDB+ patients and 103,731 (61.3 %) SDB-
patients died (Table 3; Fig. 1a). SDB diagnosis was asso-
ciated with a slight survival advantage, which dissipated
over time (Fig. 1a). The unadjusted hazard ratio (HR) for
death was 0.96 (95 % CI: 0.93–0.98) in the SDB+ vs. the
SDB- group (Fig. 2). When adjusting for demographic
characteristics (Model 1) and for BMI (Model 2), SDB+
patients had higher mortality (Model 2 HR 1.09, 95 %
CI: 1.06–1.11). However, after adjusting for all additional
baseline characteristics (Model 3), the SDB+ group had
lower associated mortality (HR: 0.93, 95 % CI: 0.91–
0.96) compared with the SDB- group.
Cardiovascular outcomes
Excluding patients who had an MI in the two years pre-
ceding ESRD, 1241 (9.9 %) of SDB+ patients and 16,217
(11.4 %) of SDB- patients had a fatal or non-fatal MI
during the study period (Table 3; Fig. 1b). We found a
lower risk for MI in the SDB+ group vs. the SDB- group
in unadjusted and adjusted models (Fig. 2).
Excluding patients who had an ischemic stroke in the
two years preceding ESRD, 576 (4.7 %) of SDB+ patients
and 8604 (5.6 %) of SDB- patients had a fatal or non-
fatal ischemic stroke during the study period (Table 3;
Fig. 1c). Similar to the results for MI, we found a lower
risk of ischemic stroke in the SDB+ group versus the
SDB- group (Fig. 2).
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Table 2 Baseline characteristics and recorded diagnoses of older individuals initiating dialysis, by presence of sleep disordered
breathing
All SDB- SDB+
N = 184,217 N = 169,096 N = 15,121
Patient demographics
Patient age 77 (72–82) 77 (72–82) 74 (70–79)
Female 46.8 47.6 37.7
Race
White 77.6 77.2 82.3
Black 18.6 18.8 16.0
Other 3.8 3.9 1.7
Hispanic ethnicity 7.4 7.6 5.6
Dual Medicare-Medicaid Eligibility 22.0 22.3 18.5
Cause of end-stage renal disease
Diabetes 39.4 38.3 51.6
Hypertension 36.8 37.4 29.0
Glomerulonephritis 5.4 5.4 4.4
Other 17.6 17.9 14.4
Missing 0.9 0.9 0.6
Dialysis modality
Hemodialysis 94.9 94.9 95.1
Peritoneal Dialysis 4.6 4.6 4.6
Missing 0.5 0.5 0.2
Skilled Nursing Facility Utilization 15.0 15.0 15.4
Hospital days (N) 5 (0–17) 5 (0–16) 6 (0–21)
Non-nephrology clinic visits (N) 19 (4–35) 18 (4–34) 28 (3–49)
Body Mass Index (BMI) (kg/m2) 26.0 (22.7–30.5) 25.7 (22.5–29.9) 31.4 (26.7–37.0)
BMI % missing data 2.0 2.0 1.8
Comorbidities
Obesity 9.5 7.4 32.5
Diabetes 62.4 60.9 78.4
Dyslipidemia 67.6 66.6 79.1
Systemic hypertension 96.9 96.7 99.1
Pulmonary hypertension 10.4 9.2 23.8
Heart failure 67.7 66.4 82.8
Valvular disease 39.0 38.3 47.2
Myocardial infarction 15.9 15.8 17.2
Unstable angina 20.7 20.3 25.3
Coronary artery bypass graft 7.7 7.5 9.9
Percutaneous coronary intervention 5.4 5.3 7.0
Peripheral vascular disease 38.3 37.9 42.6
Cerebrovascular disease 26.4 25.2 28.8
Ischemic stroke 16.8 16.7 18.0
Transient ischemic attack 7.8 7.7 8.8
Central nervous system bleed 1.5 1.5 1.8
Atrial fibrillation 32.1 31.2 42.8
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Excluding patients who had diagnosed atrial fibrillation
in the two years preceding ESRD, 2369 (27.4 %) of SDB+
patients and 30,745 (26.4 %) of SDB- patients developed
new atrial fibrillation during follow up (Table 3; Fig. 1d).
In contrast the results for MI and ischemic stroke, SDB
was associated with higher incidence of newly diagnosed
atrial fibrillation in unadjusted models (HR 1.10; 95 % CI:
1.06–1.15; Fig. 2). However, the results were no longer sta-
tistically significant in fully adjusted analyses (Model 3
HR: 1.02, 95 % CI: 0.98–1.07; Fig. 2).
Table 2 Baseline characteristics and recorded diagnoses of older individuals initiating dialysis, by presence of sleep disordered
breathing (Continued)
Ventricular fibrillation 8.5 8.1 13.2
Other cardiac arrhythmias 21.7 21.2 27.3
Pacemaker 4.6 4.5 6.4
Implantable cardiac defibrillator 2.4 2.2 4.2
Hypothyroidism 22.0 21.6 26.3
Hyperparathyroidism 5.5 5.5 6.2
Cancer 21.6 21.7 20.9
Liver disease 7.5 7.4 8.3
Lung disease 42.4 40.4 64.8
Rheumatologic disease 5.7 5.6 6.9
Gastrointestinal Bleed 21.5 21.2 24.5
Peptic ulcer disease 4.1 4.1 4.2
Human Immunodeficiency Virus 0.1 0.1 0.1
Paralysis 3.1 3.1 3.2
Depression 12.9 12.5 17.9
Dementia 10.5 10.5 10.2
Psychosis 4.9 4.8 5.7
Alcohol abuse 1.7 1.7 1.4
Tobacco abuse 5.9 6.0 5.0
Drug abuse 1.2 1.2 1.7
Acidosis 22.8 23.0 20.8
Alkalosis 1.8 1.7 3.9
Mixed acid–base disorder 1.4 1.3 2.5
Hyponatremia 14.1 13.9 16.1
Hypernatremia 3.6 3.5 4.5
Hypokalemia 14.0 13.6 18.2
Hyperkalemia 31.9 31.7 34.1
Hypocalcemia 3.3 3.4 2.5
Hypercalcemia 2.9 2.9 3.1
Disorders of phosphorus metabolism 4.0 4.0 3.9
Disorders of magnesium metabolism 3.2 3.1 3.7
Laboratory measurements
Albumin, g/dL 3.2 (2.7–3.6) 3.2 (2.7–3.6) 3.2 (2.8–3.6)
Albumin % missing data 24.4 24.3 25.8
Hemoglobin, g/dL 10.2 (9.2–11.2) 10.2 (9.2–11.2) 10.2 (9.3–11.3)
Hemoglobin % missing data 8.8 8.8 9.4
Estimated glomerular filtration rate (eGFR), mL/min/1.73 m2 10.7 (8.0–14.2) 10.6 (7.9–14.1) 12.0 (9.1–15.9)
eGFR % missing data 2.7 2.6 3.7
SDB sleep disordered breathing
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Sensitivity analyses
In sensitivity analyses using only the more specific obstruct-
ive sleep apnea (OSA) diagnosis code, we found that of
81,538 patients, 5448 (6.3 %) had a diagnosis code for OSA.
The point estimates of the hazard ratios for death, stroke,
and atrial fibrillation were similar using the OSA definition
as compared to the SDB definition (Fig. 3). However, given
the smaller sample sizes, the confidence intervals were
wider, and some results were no longer statistically signifi-
cant. The point estimates of the hazard ratios for MI in the
SDB+ vs. the SDB- group were slightly higher in the sensi-
tivity analysis than in the primary analysis and non-
significant for all four models.
Sensitivity analyses using a competing risks approach
did not materially change our results (data not shown).
Discussion
In this large population of older patients initiating dialysis,
diagnosis of SDB in the two years prior to ESRD was asso-
ciated with slightly elevated risks of death and atrial fibril-
lation, and no difference in risks of MI or ischemic stroke
when controlling for demographic factors and BMI
(Model 2). However, after additional adjustment for a
large number of pre-existing comorbid conditions, labora-
tory values, cause of ESRD, dialysis modality, and several
health care utilization variables (Model 3), SDB was asso-
ciated with lower risks of death, MI, and ischemic stroke,
while no association was found with incident atrial fibrilla-
tion. A sensitivity analysis using the more specific diagno-
sis of OSA yielded similar results. Overall, this study does
not provide evidence supporting a strong association of
SDB with mortality or cardiovascular outcomes in older,
incident dialysis patients.
Our findings were in contrast with several studies con-
ducted in the general population, which suggested that
SDB was a strong and treatable risk factor for cardiovascu-
lar events. In a prospective cohort of men and women over
50 years old from outpatient sleep clinics [3, 10], severe
OSA was associated with incident coronary events and car-
diovascular death (HR 2.82, CI 1.46–5.45). In the same
study, mild OSA was associated with stroke or transient is-
chemic attack (relative risk [RR] 3.02; CI 1.27–7.21), but
not with mortality (HR 1.70, CI 0.92–3.16). In the Sleep
Heart Health Study [8], a large U.S. multi-center
community-based prospective cohort of patients over
40 years old, moderate to severe OSA was associated with
increased risk for incident stroke in men (HR 2.86, CI
1.10–7.39), but was not associated with incident MI, death
from MI, or need for revascularization [9] . However, the
mean age in the Sleep Heart Health Study was substantially
younger than in our cohort. A Spanish study of
community-dwelling elderly patients over 70 years of age
did find an increased risk of ischemic stroke with severe
OSA (HR 2.52, CI 1.04–6.10), but this analysis did not con-
trol for important potential confounders such as comorbid
conditions or BMI.7
Multiple studies in the general population have found an
association between SDB and atrial fibrillation [12–15].
SDB has also been associated with recurrent atrial fibrilla-
tion after ablation [31], and apneic events have been shown
to directly trigger nocturnal arrhythmias [16]. Our findings
in patients with ESRD are largely consistent, though the as-
sociation we found was fairly weak. As with MI and stroke,
this could partly reflect age differences. In a study of pa-
tients without baseline atrial fibrillation undergoing poly-
somnography at the Mayo Clinic in Minnesota, mild or
worse OSA (AHI > 5) was associated with incident atrial
fibrillation in patients under 65, but not in patients over 65
[13]. In the Sleep Heart Health Study, SDB was associated
with nocturnal arrhythmias, but there was attenuation of
risk with increasing age [14]. More recently, a study of
community-dwelling men over 65 years of age (Outcomes
of Sleep Disorders in Older Men Study) did find an inde-
pendent association between severity of SDB and incident
atrial fibrillation [15]. In particular, central sleep apnea
(CSA) was more strongly associated with atrial fibrillation,
whereas OSA was more closely associated with complex
ventricular ectopy. Given that CSA may be more prevalent
in ESRD, a stronger association between SDB and atrial fib-
rillation might have been expected, but this was not the
case.
A few small studies have already been conducted on SDB
and cardiovascular events in ESRD. In a cohort (n = 50) of
Italian patients with ESRD, an independent association was
found between nocturnal hypoxemia and cardiovascular
Table 3 Follow-up and study outcomes
Outcome SDB- SDB+
Death N = 169,096 N = 15,121
Number of events 103,731 8248
Person-time at risk (years) 271,789 22,434
Incidence rate (events/100 person-years) 38.2 36.8
Myocardial infarction (non-fatal or fatal) N = 142,355 N = 12,525
Number of events 16,217 1241
Person-time at risk (years) 216,722 17,639
Incidence rate (events/100 person-years) 7.48 7.04
Ischemic stroke (non-fatal or fatal) N = 140,795 N = 12,399
Number of events 8604 576
Person-time at risk (years) 222,419 17,962
Incidence rate (events/100 person-years) 3.87 3.21
Incident atrial fibrillation N = 116,425 N = 8644
Number of events 30,745 2369
Person-time at risk (years) 166,609 11,416
Incidence rate (events/100 person-years) 18.5 20.8
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events [32]. Recently, two small studies of patients under-
going peritoneal dialysis in Taiwan (n = 93) and
hemodialysis in Japan (n = 94) found significant independ-
ent associations between SDB and cardiovascular events
[33, 34]. These studies differ from ours in that they were
conducted in small groups of selected patients attending
sleep clinics and assessed a broader range of cardiovascular
outcomes (including heart failure, angina, other arrhyth-
mias) as a combined outcome. They also used polysomno-
graphy to screen for SDB, an advantage over our study
design. In contrast to their findings, our study suggests that
while SDB may be a contributor to incident atrial fibrilla-
tion, it is probably not a significant factor driving cardiovas-
cular events and mortality in patients with ESRD.
There are several reasons why SDB might be a less power-
ful risk factor for cardiovascular events in ESRD. Fluid shifts,
heart failure, fluid overload, uremia, and other ESRD-
specific factors may contribute to the pathophysiology of
SDB and differentially mediate cardiovascular risk. Indeed,
prior research suggests that risk factors for SDB differ in pa-
tients with ESRD, and that SDB may present somewhat dif-
ferently [35]. In the dialysis population, SDB may be more
frequently central rather than obstructive [24], and these pa-
tients may present with less “Pickwickian” features [35].
There are also strong competing risks for cardiovascular
events in ESRD, which could attenuate the effect of SDB. It
is also relevant that comorbidities associated with SDB (e.g.,
diabetes and the metabolic syndrome) probably contribute
to the development of ESRD in the first place. It has even
been suggested that SDB might independently contribute to
chronic kidney disease [36], but once ESRD is reached, SDB
might become less important. That is, if patients with SDB
are more likely to die before developing ESRD, then those
patients initiating dialysis constitute the “surviving fittest”.
There are several examples of established risk factors for
cardiovascular disease that are paradoxically protective in
Fig. 1 Kaplan-Meier Product Limit Estimates of Study Outcomes. Panel a Patient Survival. Panel b Myocardial Infarction. Panel c Ischemic Stroke.
Panel d Atrial Fibrillation
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ESRD, such as obesity and higher blood pressure, which are
associated with longer survival in patients on dialysis [37–39].
Similar explanations may be relevant to SDB in ESRD.
Our study has a few important limitations. First, we
used Medicare claims diagnosis codes to identify patient
with SDB rather than polysomnography, the diagnostic
gold standard. Estimates of the prevalence of sleep apnea
in the ESRD population using polysomnography range
from 30 to 80 % [24, 40], although the prevalence of SDB
in older patients with ESRD has not been established. SDB
is generally underrecognized, and it may be further under-
diagnosed in patients with ESRD due to attention placed
on other health concerns or because of the different char-
acteristics of SDB in this population. The prevalence of
SDB was only ~8 % in our study, reflecting underdiagno-
sis. We did not have clinical information on polysomno-
graphy or specific treatments for SDB in this study. There
is potential for bias if patients diagnosed with SDB were
systematically different from those with occult SDB. Pa-
tients with ESRD often have a high burden of comorbid
illness, can be physically limited, and carry a poor progno-
sis, so perhaps healthier patients with SDB were more
likely undergo work-up. However, it is plausible to con-
sider that patients diagnosed with SDB were the most se-
vere cases, which makes the lack, or paradoxical direction,
of the associations found even more striking. Several base-
line factors may have been causes, some consequences,
and again some both causes and consequences of the ex-
posure of interest. Owing to the timeline of available data,
we were unable to distinguish among these categories.
Hence, the true associations are likely to be bound by the
respective associations in models 1 and 3. Another poten-
tial confounder may be differences in access to care, with
better access leading to higher probability of SDB diagno-
sis and thus better outcomes. However, at the very least all
patients in this study had continuous insurance coverage
Hazard Ratio (95% CI)
Model 3
Model 2
Model 1
Unadjusted
0.8 1.0 1.2
0.83 (0.76−0.9)
0.91 (0.83−0.99)
0.95 (0.87−1.04)
0.9 (0.82−0.98)
Ischemic Stroke
0.8 1.0 1.2
1.1 (1.06−1.15)
1.15 (1.1−1.2)
1.13 (1.09−1.18)
1.02 (0.98−1.07)
Atrial Fibrillation
Model 3
Model 2
Model 1
Unadjusted 0.96 (0.93−0.98)
1.03 (1.01−1.06)
1.09 (1.06−1.11)
0.93 (0.91−0.96)
Death
0.93 (0.88−0.99)
0.95 (0.9−1.01)
0.98 (0.92−1.04)
0.92 (0.87−0.98)
Myocardial Infarction
Fig. 2 Unadjusted and Adjusted Hazard Ratios for Study Outcomes. Stratified Cox analysis with multiple imputation to handle missing data. All
models stratified by Year of dialysis initiation. Model 1 is adjusted for age, sex, race, Hispanic ethnicity, and Medicaid eligibility. Model 2 is
additionally adjusted for BMI. Model 3 is additionally adjusted for all covariates in Table 1. Ischemic stroke includes events related to death from
any kind of stroke. Myocardial infarction includes death from myocardial infarction
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for at least 2 years prior to ESRD through the federal
Medicare program. Our study did not include patients
under 67 years of age, in younger patients we would not
have pre-ESRD Medicare claims for study (the age thresh-
old for Medicare eligibility is 65 years), so our findings
may not be generalizable to younger individuals with
ESRD. Finally, follow-up was relatively short in this study
mostly owing to the very high mortality rate (~38 deaths
per 100 person-years) in this population of older patients
with ESRD.
Our study has several strengths, especially its national
scope and broad generalizability to the older U.S. dialysis
population. Patients with and without diagnosed SDB
were also well characterized on a wide range of demo-
graphic characteristics, comorbid conditions, and labora-
tory variables, using data from several sources. We
found that SDB diagnosis was associated with higher
prevalence of several baseline comorbid diagnoses in-
cluding obesity, diabetes, hyperlipidemia, depression,
cardiovascular disease, heart failure, arrhythmias, and
pulmonary hypertension, all of which have been associ-
ated with SDB in the general population.
Conclusions
In summary, in demographics and BMI-adjusted analyses
physician-diagnosed SDB was associated with slightly in-
creased risks of mortality and atrial fibrillation, and no dif-
ference in the risks of myocardial infarction or ischemic
stroke in older patients initiating dialysis. Adjustment for a
large number of comorbidities and other parameters
yielded protective associations between SDB and most car-
diovascular outcomes. Though we cannot exclude the pos-
sibility that SDB diagnosed by polysomnography would
carry different cardiovascular risks, our study suggests that
Hazard Ratio (95% CI)
Model 3
Model 2
Model 1
Unadjusted
0.8 1.0 1.2
0.8 (0.67−0.95)
0.88 (0.74−1.05)
0.91 (0.76−1.1)
0.86 (0.71−1.04)
Ischemic Stroke
0.8 1.0 1.2
1.1 (1.01−1.19)
1.14 (1.05−1.24)
1.12 (1.03−1.22)
1.01 (0.93−1.1)
Atrial Fibrillation
Model 3
Model 2
Model 1
Unadjusted 0.93 (0.89−0.98)
1.02 (0.98−1.07)
1.07 (1.02−1.12)
0.91 (0.87−0.96)
Death
0.99 (0.88−1.11)
1.02 (0.91−1.14)
1.06 (0.94−1.18)
1 (0.89−1.13)
Myocardial Infarction
Fig. 3 Sensitivity Analysis: Unadjusted and Adjusted Hazard Ratios for Study Outcomes using Obstructive Sleep Apnea Definition, 2007–2009.
Stratified Cox analysis with multiple imputation to handle missing data. All models stratified by Year of dialysis initiation. Model 1 is adjusted for
age, sex, race, Hispanic ethnicity, and Medicaid eligibility. Model 2 is additionally adjusted for BMI. Model 3 is additionally adjusted for all
covariates in Table 1. Ischemic stroke includes events related to death from any kind of stroke. Myocardial infarction includes death from
myocardial infarction
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SDB may not be as important a risk factor for cardiovascu-
lar events or atrial fibrillation in older patients with ESRD
as in the general population. Further studies are needed to
explain our findings, especially ones that prospectively
screen patients for SDB using validated screening methods
(questionnaires) or accepted testing methods. Studies are
also needed to assess the effect of treatments for SDB such
as CPAP and alternative dialysis modalities on cardiovascu-
lar outcomes. With improved understanding of this poten-
tial risk factor for cardiovascular disease, we can better
inform the screening and treatment decisions of providers
caring for patients living with ESRD.
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